View Financial HealthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsAntibe Therapeutics 配当と自社株買い配当金 基準チェック /06Antibe Therapeutics配当金を支払った記録がありません。主要情報n/a配当利回り0%バイバック利回り総株主利回り0%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Mar 19Taro Pharmaceuticals Inc. completed the acquisition of Antibe Therapeutics Inc. for CAD 4.5 million.Taro Pharmaceuticals Inc. agreed to acquire Antibe Therapeutics Inc. on January 15, 2025. A cash consideration will be paid by Taro Pharmaceuticals Inc. The transaction is subject to subject to court approval. The expected completion of the transaction is March 7, 2025. Taro Pharmaceuticals Inc. completed the acquisition of Antibe Therapeutics Inc. for CAD 4.5 million on March 17, 2025.お知らせ • Jan 16Taro Pharmaceuticals Inc. agreed to acquire Antibe Therapeutics Inc.Taro Pharmaceuticals Inc. agreed to acquire Antibe Therapeutics Inc. on January 16, 2025. A cash consideration will be paid by Taro Pharmaceuticals Inc. The transaction is subject to subject to court approval. The expected completion of the transaction is March 7, 2025.お知らせ • Apr 24Antibe Therapeutics Inc. Announces Board ResignationsAntibe Therapeutics Inc. announced that Roderick Flower, Robert Hoffman, Dan Legault, Walt Macnee and Yung Wu have resigned from Antibe’s Board of Directors.お知らせ • Apr 09Antibe Therapeutics Inc. Announces Board ResignationsAntibe Therapeutics Inc. announced that Amal Khouri and Jennifer McNealey have resigned from its Board of Directors effective April 8, 2024.お知らせ • Apr 02+ 2 more updatesNuance Pharma Limited Commences Legal Action Against Antibe Therapeutics Inc. in the Ontario Superior Court Legal ActionAntibe Therapeutics Inc. announced that Nuance Pharma Limited has commenced legal action in the Ontario Superior Court of Justice to seek recognition of and enforce the arbitration award in Ontario previously announced by Antibe in its press release of March 4, 2024. Nuance Pharma is seeking the appointment of a receiver as part of its relief; a hearing date has not been set.お知らせ • Nov 10Antibe Therapeutics Inc. Reports PK Results of First Clinical Study of Otenaproxesul’s New FormulationAntibe Therapeutics Inc. announced the PK results of the pharmacokinetic/pharmacodynamic ("PK/PD") study of otenaproxesul's faster-absorbing formulation. The study was designed to confirm the drug's safety and inform the selection of treatment regimens for the upcoming Phase II trial, on track to launch in calendar First Quarter 2024. The PK/PD study involved 36 healthy volunteers, randomized across three treatment arms: a single high dose and two five-day regimens of o tenaproxesul. Subjects remained in-clinic for the duration of their treatment. As previously reported, all subjects completed the study with no clinically significant, drug-related adverse events and no increase in liver enzymes. In line with preclinical data and DILIsym liver safety modeling, the study confirmed the new formulation's linear, dose-proportional PK, with substantially lower doses needed to achieve target plasma levels compared to the original formulation. More rapid elimination was also observed, expanding the drug's safety envelope. These data provide the basis for selecting treatment regimens to achieve the pain relief expectations of patients, doctors and regulators. They also advance Antibe's exploration of potential treatment regimens for chronic pain.お知らせ • Nov 02Antibe Completes First Clinical Study of Otenaproxesul’s New FormulationAntibe Therapeutics Inc. announced the completion of the pharmacokinetic/pharmacodynamic (“PK/PD”) study of otenaproxesul’s faster-absorbing formulation for acute pain. The study was designed to confirm the drug’ssafety and inform treatment regimens for the upcoming Phase II trial, on track to launch in calendar First Quarter 2024. The PK/PD study involved 36 healthy volunteers randomized across three treatment arms: a single high dose and two five-day regimens of otenaproxesul. The five-day regimens were chosen to correspond to regimens envisaged for the upcoming Phase II trial. Subjects remained in-clinic for the duration of their treatment. All subjectscompleted the study with no clinically significant, drug-related adverse events and no elevation in liver enzymes during treatment or in post-treatment follow up.お知らせ • Oct 19Antibe Initiates First Clinical Study of Otenaproxesul’s New FormulationAntibe Therapeutics Inc. announce the initiation of the pharmacokinetic/pharmacodynamic (“PK/PD”) study of otenaproxesul’s faster-absorbing formulation for acute pain. The study is designed to inform the doses and confirm safety in preparation for the Phase II trial, on track to launch in calendar First Quarter 2024. The PK/PD study will involve 36 healthy volunteers randomized across three treatment arms: a single high dose and two five-day regimens of otenaproxesul. Subjects will remain in-clinic for the duration of their treatment. Expected in November, the study data will also advance Antibe’s exploration of potential treatment regimens for chronic pain.お知らせ • Sep 29Antibe Therapeutics Inc. Receives Approval to Initiate PK/PD Study of OtenaproxesulAntibe Therapeutics Inc. announced Health Canada's approval to initiate the pharmacokinetic/pharmacodynamic study of otenaproxesul's faster-absorbing formulation for acute pain. Set to commence in October, the purpose of the study is to inform the doses for the Phase II trial.お知らせ • Jul 01Antibe Therapeutics Inc., Annual General Meeting, Sep 08, 2023Antibe Therapeutics Inc., Annual General Meeting, Sep 08, 2023. Location: Toronto, ON Toronto Canadaお知らせ • Feb 16Antibe Therapeutics Inc. Announces Retirement of Dr. John L. Wallace from the Board of DirectorsAntibe Therapeutics Inc. announced that its founder, Dr. John L. Wallace, has decided to retire from the Board of Directors. Dr. Wallace will remain a corporate Vice Chair, enabling the company to continue to benefit from his wisdom and expertise.決済の安定と成長配当データの取得安定した配当: ATBP.Fの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: ATBP.Fの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Antibe Therapeutics 配当利回り対市場ATBP.F 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (ATBP.F)n/a市場下位25% (US)1.3%市場トップ25% (US)4.0%業界平均 (Pharmaceuticals)1.9%アナリスト予想 (ATBP.F) (最長3年)n/a注目すべき配当: ATBP.Fは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: ATBP.Fは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: ATBP.Fの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: ATBP.Fが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/05/28 12:09終値2024/04/08 00:00収益2023/12/31年間収益2023/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Antibe Therapeutics Inc. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7 アナリスト機関Sally YanchusBrookline Capital MarketsTania Armstrong-WhitworthCanaccord GenuityDouglas LoeLeede Financial Inc4 その他のアナリストを表示
お知らせ • Mar 19Taro Pharmaceuticals Inc. completed the acquisition of Antibe Therapeutics Inc. for CAD 4.5 million.Taro Pharmaceuticals Inc. agreed to acquire Antibe Therapeutics Inc. on January 15, 2025. A cash consideration will be paid by Taro Pharmaceuticals Inc. The transaction is subject to subject to court approval. The expected completion of the transaction is March 7, 2025. Taro Pharmaceuticals Inc. completed the acquisition of Antibe Therapeutics Inc. for CAD 4.5 million on March 17, 2025.
お知らせ • Jan 16Taro Pharmaceuticals Inc. agreed to acquire Antibe Therapeutics Inc.Taro Pharmaceuticals Inc. agreed to acquire Antibe Therapeutics Inc. on January 16, 2025. A cash consideration will be paid by Taro Pharmaceuticals Inc. The transaction is subject to subject to court approval. The expected completion of the transaction is March 7, 2025.
お知らせ • Apr 24Antibe Therapeutics Inc. Announces Board ResignationsAntibe Therapeutics Inc. announced that Roderick Flower, Robert Hoffman, Dan Legault, Walt Macnee and Yung Wu have resigned from Antibe’s Board of Directors.
お知らせ • Apr 09Antibe Therapeutics Inc. Announces Board ResignationsAntibe Therapeutics Inc. announced that Amal Khouri and Jennifer McNealey have resigned from its Board of Directors effective April 8, 2024.
お知らせ • Apr 02+ 2 more updatesNuance Pharma Limited Commences Legal Action Against Antibe Therapeutics Inc. in the Ontario Superior Court Legal ActionAntibe Therapeutics Inc. announced that Nuance Pharma Limited has commenced legal action in the Ontario Superior Court of Justice to seek recognition of and enforce the arbitration award in Ontario previously announced by Antibe in its press release of March 4, 2024. Nuance Pharma is seeking the appointment of a receiver as part of its relief; a hearing date has not been set.
お知らせ • Nov 10Antibe Therapeutics Inc. Reports PK Results of First Clinical Study of Otenaproxesul’s New FormulationAntibe Therapeutics Inc. announced the PK results of the pharmacokinetic/pharmacodynamic ("PK/PD") study of otenaproxesul's faster-absorbing formulation. The study was designed to confirm the drug's safety and inform the selection of treatment regimens for the upcoming Phase II trial, on track to launch in calendar First Quarter 2024. The PK/PD study involved 36 healthy volunteers, randomized across three treatment arms: a single high dose and two five-day regimens of o tenaproxesul. Subjects remained in-clinic for the duration of their treatment. As previously reported, all subjects completed the study with no clinically significant, drug-related adverse events and no increase in liver enzymes. In line with preclinical data and DILIsym liver safety modeling, the study confirmed the new formulation's linear, dose-proportional PK, with substantially lower doses needed to achieve target plasma levels compared to the original formulation. More rapid elimination was also observed, expanding the drug's safety envelope. These data provide the basis for selecting treatment regimens to achieve the pain relief expectations of patients, doctors and regulators. They also advance Antibe's exploration of potential treatment regimens for chronic pain.
お知らせ • Nov 02Antibe Completes First Clinical Study of Otenaproxesul’s New FormulationAntibe Therapeutics Inc. announced the completion of the pharmacokinetic/pharmacodynamic (“PK/PD”) study of otenaproxesul’s faster-absorbing formulation for acute pain. The study was designed to confirm the drug’ssafety and inform treatment regimens for the upcoming Phase II trial, on track to launch in calendar First Quarter 2024. The PK/PD study involved 36 healthy volunteers randomized across three treatment arms: a single high dose and two five-day regimens of otenaproxesul. The five-day regimens were chosen to correspond to regimens envisaged for the upcoming Phase II trial. Subjects remained in-clinic for the duration of their treatment. All subjectscompleted the study with no clinically significant, drug-related adverse events and no elevation in liver enzymes during treatment or in post-treatment follow up.
お知らせ • Oct 19Antibe Initiates First Clinical Study of Otenaproxesul’s New FormulationAntibe Therapeutics Inc. announce the initiation of the pharmacokinetic/pharmacodynamic (“PK/PD”) study of otenaproxesul’s faster-absorbing formulation for acute pain. The study is designed to inform the doses and confirm safety in preparation for the Phase II trial, on track to launch in calendar First Quarter 2024. The PK/PD study will involve 36 healthy volunteers randomized across three treatment arms: a single high dose and two five-day regimens of otenaproxesul. Subjects will remain in-clinic for the duration of their treatment. Expected in November, the study data will also advance Antibe’s exploration of potential treatment regimens for chronic pain.
お知らせ • Sep 29Antibe Therapeutics Inc. Receives Approval to Initiate PK/PD Study of OtenaproxesulAntibe Therapeutics Inc. announced Health Canada's approval to initiate the pharmacokinetic/pharmacodynamic study of otenaproxesul's faster-absorbing formulation for acute pain. Set to commence in October, the purpose of the study is to inform the doses for the Phase II trial.
お知らせ • Jul 01Antibe Therapeutics Inc., Annual General Meeting, Sep 08, 2023Antibe Therapeutics Inc., Annual General Meeting, Sep 08, 2023. Location: Toronto, ON Toronto Canada
お知らせ • Feb 16Antibe Therapeutics Inc. Announces Retirement of Dr. John L. Wallace from the Board of DirectorsAntibe Therapeutics Inc. announced that its founder, Dr. John L. Wallace, has decided to retire from the Board of Directors. Dr. Wallace will remain a corporate Vice Chair, enabling the company to continue to benefit from his wisdom and expertise.